🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 35 of 55

  1. ORSERDU 86 mg film-coated tablets, LETROZOLE , -, ORSERDU 345 mg film-coated tablets, Kisqali 200 mg film-coated tablets, EXEMESTANE , ANASTROZOLE

    Shanghai Reinovax Biologics Co.,LTD

    endocrine-responsive HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  2. ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Stemline Therapeutics B.V.

    metastatic breast cancer

    phase 2 small molecule active

    1 trial

  3. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb Australia Pty Ltd

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  4. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  5. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  7. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  8. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  9. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  10. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  11. Obatoclax

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  12. Obatoclax Mesylate

    Teva Pharma GmbH

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  13. Obatoclax mesylate

    Teva Pharma GmbH

    Mantle-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  14. Obatoclax mesylate

    Teva Pharma GmbH

    Lymphoma, Follicular

    phase 2 small molecule completed

    1 trial

  15. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  16. Obatoclax mesylate 250 ml

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. Obecabtagene Autoleucel

    Autolus GmbH

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  18. Obecabtagene autoleucel

    Autolus GmbH

    Acute Lymphocytic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  19. Obinutuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  20. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial

  21. Obinutuzumab

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  22. Odomzo 200 mg hard capsules

    Fondazione Telethon ETS

    locally advanced basal cell carcinoma

    phase 2 small molecule active

    1 trial

  23. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkin Lymphoma (B-NHL)

    phase 2 small molecule active

    2 trials

  24. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma

    phase 2 mab active

    1 trial

  25. Odronextamab

    Regeneron UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 2 mab active

    1 trial

  26. Odronextamab, Odronextamab, Odronextamab

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  27. Ogivri 150 mg powder for concentrate for solution for infusion, TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  28. Olaparib

    United Therapeutics Europe Ltd

    Bile Duct Adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  30. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  31. Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  32. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  33. Oleclumab, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, PACLITAXEL, Capivasertib, DS-8201a

    AstraZeneca AB

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    phase 2 small molecule active

    1 trial

  34. Olumiant 2 mg film-coated tablets, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    -women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm. -male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor board

    phase 2 small molecule active

    1 trial

  35. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  36. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  37. Olverembatinib

    The First People's Hospital of Lianyungang

    Myeloproliferative Neoplasm

    phase 2 small molecule active

    1 trial

  38. Olverembatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  39. Omacetaxine

    Teva Pharma GmbH

    Leukemia

    phase 2 small molecule terminated

    2 trials

  40. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  41. Omacetaxine mepesuccinate

    Teva Pharma GmbH

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    3 trials

  42. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  43. Onapristone

    Context Therapeutics

    ER-positive Breast Cancer

    phase 2 small molecule terminated

    1 trial

  44. Onapristone ER

    Context Therapeutics

    Granulosa Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  45. OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., N-803 (NAI), OncoTICE® 2-8 x 108 vermehrungsfähige Einheiten Pulver zur Herstellung einer Suspension zur intravesikalen Instillation

    Immunitybio Ireland Limited

    Non-Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  46. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  48. Onvansertib

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.